Recurrent Lung Cancer – Non-Small Cell

Novel PD-1 Inhibitor Opdivo Approved for Treatment of Lung Cancer (03-11-2015)

The Food and Drug Administration has expanded approval of the PD-1 inhibitor Opdivo® (nivolumab) to include treatment of patients who have metastatic squamous non–small cell lung cancer (NSCLC) that progresses following treatment with platinum-based... Continue Reading

Study Using Comprehensive Genomic Tumor Testing to Match Lung Cancer Patients with Targeted Therapies Transforms Care (05-22-2014)

Data Supports Routine Tumor Genotyping for Patients with Advanced Lung Cancers; May Improve Survival New data from a study led by Memorial Sloan Kettering physicians that used targeted therapy for patients with the most common type of lung cancer has... Continue Reading